Phase 4 Trial of Ixinity for Pediatric Hemophilia B Is Fully Enrolled

Phase 4 Trial of Ixinity for Pediatric Hemophilia B Is Fully Enrolled

302925

Phase 4 Trial of Ixinity for Pediatric Hemophilia B Is Fully Enrolled

Medexus Pharmaceuticals has completed patient enrollment in its clinical trial investigating Ixinity as a preventive treatment for children younger than 12 with hemophilia B.  The open-label Phase 4 trial (NCT03855280) achieved its target enrollment goal of 22 participants and is being conducted in 15 centers in Brazil, Colombia, Moldova, South Africa, and Ukraine. Results from the study are expected to be submitted to the U.S. Food and Drug Administration (FDA) by the end of 2022.…

You must be logged in to read/download the full post.